COVID-19 Impact on Global Primary Sclerosing Cholangitis Treatment Market Size, Status and Forecast 2020-2026

August 2020 | 132 pages | ID: C7A7A44100ACEN
QYResearch

Abstracts

This report focuses on the global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Allergan
• Glenmark
• Impax Laboratories
• Mylan
• Teva Pharmaceuticals
• Dr. Falk Pharma
• Daewoong Pharmaceutical
• Epic Pharma
• Mitsubishi Tanabe Pharma
• Lannett
• Bruschettini
• Shanghai Pharma
• Grindeks
• Acorda Therapeutics
• Gilead Sciences
• Intercept Pharmaceuticals
• Shire Plc
• NGM Biopharmaceuticals
• Conatus Pharmaceuticals
• Durect Corporation
• Sirnaomics
• Shenzhen HighTide Biopharmaceuticals

Market segment by Type, the product can be split into

• Liver Transplantation Operation
• UDCA Drugs
• PSC Drugs

Market segment by Application, split into

• Hospital
• Clinics
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Primary Sclerosing Cholangitis Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Primary Sclerosing Cholangitis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Primary Sclerosing Cholangitis Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Liver Transplantation Operation
  1.4.3 UDCA Drugs
  1.4.4 PSC Drugs
1.5 Market by Application
  1.5.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinics
  1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Primary Sclerosing Cholangitis Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Primary Sclerosing Cholangitis Treatment Industry
    1.6.1.1 Primary Sclerosing Cholangitis Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Primary Sclerosing Cholangitis Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Primary Sclerosing Cholangitis Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Primary Sclerosing Cholangitis Treatment Market Perspective (2015-2026)
2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Regions
  2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Primary Sclerosing Cholangitis Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Primary Sclerosing Cholangitis Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Market Size
  3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2015-2020)
  3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
  3.2.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2019
3.3 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
3.4 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
3.5 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2021-2026)

5 PRIMARY SCLEROSING CHOLANGITIS TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
6.2 Primary Sclerosing Cholangitis Treatment Key Players in North America (2019-2020)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
7.2 Primary Sclerosing Cholangitis Treatment Key Players in Europe (2019-2020)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
8.2 Primary Sclerosing Cholangitis Treatment Key Players in China (2019-2020)
8.3 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
8.4 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
9.2 Primary Sclerosing Cholangitis Treatment Key Players in Japan (2019-2020)
9.3 Japan Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
9.4 Japan Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
10.2 Primary Sclerosing Cholangitis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
11.2 Primary Sclerosing Cholangitis Treatment Key Players in India (2019-2020)
11.3 India Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
11.4 India Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Primary Sclerosing Cholangitis Treatment Market Size (2015-2020)
12.2 Primary Sclerosing Cholangitis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Allergan
  13.1.1 Allergan Company Details
  13.1.2 Allergan Business Overview and Its Total Revenue
  13.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
  13.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020))
  13.1.5 Allergan Recent Development
13.2 Glenmark
  13.2.1 Glenmark Company Details
  13.2.2 Glenmark Business Overview and Its Total Revenue
  13.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
  13.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.2.5 Glenmark Recent Development
13.3 Impax Laboratories
  13.3.1 Impax Laboratories Company Details
  13.3.2 Impax Laboratories Business Overview and Its Total Revenue
  13.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
  13.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.3.5 Impax Laboratories Recent Development
13.4 Mylan
  13.4.1 Mylan Company Details
  13.4.2 Mylan Business Overview and Its Total Revenue
  13.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
  13.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.4.5 Mylan Recent Development
13.5 Teva Pharmaceuticals
  13.5.1 Teva Pharmaceuticals Company Details
  13.5.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
  13.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
  13.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.5.5 Teva Pharmaceuticals Recent Development
13.6 Dr. Falk Pharma
  13.6.1 Dr. Falk Pharma Company Details
  13.6.2 Dr. Falk Pharma Business Overview and Its Total Revenue
  13.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
  13.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.6.5 Dr. Falk Pharma Recent Development
13.7 Daewoong Pharmaceutical
  13.7.1 Daewoong Pharmaceutical Company Details
  13.7.2 Daewoong Pharmaceutical Business Overview and Its Total Revenue
  13.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
  13.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.7.5 Daewoong Pharmaceutical Recent Development
13.8 Epic Pharma
  13.8.1 Epic Pharma Company Details
  13.8.2 Epic Pharma Business Overview and Its Total Revenue
  13.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
  13.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.8.5 Epic Pharma Recent Development
13.9 Mitsubishi Tanabe Pharma
  13.9.1 Mitsubishi Tanabe Pharma Company Details
  13.9.2 Mitsubishi Tanabe Pharma Business Overview and Its Total Revenue
  13.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
  13.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.9.5 Mitsubishi Tanabe Pharma Recent Development
13.10 Lannett
  13.10.1 Lannett Company Details
  13.10.2 Lannett Business Overview and Its Total Revenue
  13.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
  13.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  13.10.5 Lannett Recent Development
13.11 Bruschettini
  10.11.1 Bruschettini Company Details
  10.11.2 Bruschettini Business Overview and Its Total Revenue
  10.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
  10.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.11.5 Bruschettini Recent Development
13.12 Shanghai Pharma
  10.12.1 Shanghai Pharma Company Details
  10.12.2 Shanghai Pharma Business Overview and Its Total Revenue
  10.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
  10.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.12.5 Shanghai Pharma Recent Development
13.13 Grindeks
  10.13.1 Grindeks Company Details
  10.13.2 Grindeks Business Overview and Its Total Revenue
  10.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
  10.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.13.5 Grindeks Recent Development
13.14 Acorda Therapeutics
  10.14.1 Acorda Therapeutics Company Details
  10.14.2 Acorda Therapeutics Business Overview and Its Total Revenue
  10.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
  10.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.14.5 Acorda Therapeutics Recent Development
13.15 Gilead Sciences
  10.15.1 Gilead Sciences Company Details
  10.15.2 Gilead Sciences Business Overview and Its Total Revenue
  10.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
  10.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.15.5 Gilead Sciences Recent Development
13.16 Intercept Pharmaceuticals
  10.16.1 Intercept Pharmaceuticals Company Details
  10.16.2 Intercept Pharmaceuticals Business Overview and Its Total Revenue
  10.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
  10.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.16.5 Intercept Pharmaceuticals Recent Development
13.17 Shire Plc
  10.17.1 Shire Plc Company Details
  10.17.2 Shire Plc Business Overview and Its Total Revenue
  10.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
  10.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.17.5 Shire Plc Recent Development
13.18 NGM Biopharmaceuticals
  10.18.1 NGM Biopharmaceuticals Company Details
  10.18.2 NGM Biopharmaceuticals Business Overview and Its Total Revenue
  10.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
  10.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.18.5 NGM Biopharmaceuticals Recent Development
13.19 Conatus Pharmaceuticals
  10.19.1 Conatus Pharmaceuticals Company Details
  10.19.2 Conatus Pharmaceuticals Business Overview and Its Total Revenue
  10.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
  10.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.19.5 Conatus Pharmaceuticals Recent Development
13.20 Durect Corporation
  10.20.1 Durect Corporation Company Details
  10.20.2 Durect Corporation Business Overview and Its Total Revenue
  10.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
  10.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.20.5 Durect Corporation Recent Development
13.21 Sirnaomics
  10.21.1 Sirnaomics Company Details
  10.21.2 Sirnaomics Business Overview and Its Total Revenue
  10.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
  10.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.21.5 Sirnaomics Recent Development
13.22 Shenzhen HighTide Biopharmaceuticals
  10.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
  10.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview and Its Total Revenue
  10.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
  10.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
  10.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Primary Sclerosing Cholangitis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
Table 3. Ranking of Global Top Primary Sclerosing Cholangitis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Liver Transplantation Operation
Table 6. Key Players of UDCA Drugs
Table 7. Key Players of PSC Drugs
Table 8. COVID-19 Impact Global Market: (Four Primary Sclerosing Cholangitis Treatment Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Primary Sclerosing Cholangitis Treatment Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Primary Sclerosing Cholangitis Treatment Players to Combat Covid-19 Impact
Table 13. Global Primary Sclerosing Cholangitis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2015-2020)
Table 17. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Primary Sclerosing Cholangitis Treatment Market Growth Strategy
Table 23. Main Points Interviewed from Key Primary Sclerosing Cholangitis Treatment Players
Table 24. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2015-2020) (Million US$)
Table 25. Global Primary Sclerosing Cholangitis Treatment Market Share by Players (2015-2020)
Table 26. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019)
Table 27. Global Primary Sclerosing Cholangitis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
Table 30. Date of Enter into Primary Sclerosing Cholangitis Treatment Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 33. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Type (2015-2020)
Table 34. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2021-2026)
Table 35. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Application (2015-2020)
Table 36. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 37. Global Primary Sclerosing Cholangitis Treatment Market Size Share by Application (2021-2026)
Table 38. North America Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 40. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 41. North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 42. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 43. North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 44. Europe Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 46. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 48. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 50. China Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 51. China Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 52. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 53. China Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 54. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 55. China Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 56. Japan Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 58. Japan Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 59. Japan Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 60. Japan Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 61. Japan Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 64. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 66. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 68. India Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 69. India Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 70. India Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 71. India Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 72. India Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 73. India Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 74. Central & South America Key Players Primary Sclerosing Cholangitis Treatment Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players Primary Sclerosing Cholangitis Treatment Market Share (2019-2020)
Table 76. Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America Primary Sclerosing Cholangitis Treatment Market Share by Type (2015-2020)
Table 78. Central & South America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America Primary Sclerosing Cholangitis Treatment Market Share by Application (2015-2020)
Table 80. Allergan Company Details
Table 81. Allergan Business Overview
Table 82. Allergan Product
Table 83. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 84. Allergan Recent Development
Table 85. Glenmark Company Details
Table 86. Glenmark Business Overview
Table 87. Glenmark Product
Table 88. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 89. Glenmark Recent Development
Table 90. Impax Laboratories Company Details
Table 91. Impax Laboratories Business Overview
Table 92. Impax Laboratories Product
Table 93. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 94. Impax Laboratories Recent Development
Table 95. Mylan Company Details
Table 96. Mylan Business Overview
Table 97. Mylan Product
Table 98. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 99. Mylan Recent Development
Table 100. Teva Pharmaceuticals Company Details
Table 101. Teva Pharmaceuticals Business Overview
Table 102. Teva Pharmaceuticals Product
Table 103. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 104. Teva Pharmaceuticals Recent Development
Table 105. Dr. Falk Pharma Company Details
Table 106. Dr. Falk Pharma Business Overview
Table 107. Dr. Falk Pharma Product
Table 108. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 109. Dr. Falk Pharma Recent Development
Table 110. Daewoong Pharmaceutical Company Details
Table 111. Daewoong Pharmaceutical Business Overview
Table 112. Daewoong Pharmaceutical Product
Table 113. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 114. Daewoong Pharmaceutical Recent Development
Table 115. Epic Pharma Business Overview
Table 116. Epic Pharma Product
Table 117. Epic Pharma Company Details
Table 118. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 119. Epic Pharma Recent Development
Table 120. Mitsubishi Tanabe Pharma Company Details
Table 121. Mitsubishi Tanabe Pharma Business Overview
Table 122. Mitsubishi Tanabe Pharma Product
Table 123. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 124. Mitsubishi Tanabe Pharma Recent Development
Table 125. Lannett Company Details
Table 126. Lannett Business Overview
Table 127. Lannett Product
Table 128. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 129. Lannett Recent Development
Table 130. Bruschettini Company Details
Table 131. Bruschettini Business Overview
Table 132. Bruschettini Product
Table 133. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 134. Bruschettini Recent Development
Table 135. Shanghai Pharma Company Details
Table 136. Shanghai Pharma Business Overview
Table 137. Shanghai Pharma Product
Table 138. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 139. Shanghai Pharma Recent Development
Table 140. Grindeks Company Details
Table 141. Grindeks Business Overview
Table 142. Grindeks Product
Table 143. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 144. Grindeks Recent Development
Table 145. Acorda Therapeutics Company Details
Table 146. Acorda Therapeutics Business Overview
Table 147. Acorda Therapeutics Product
Table 148. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 149. Acorda Therapeutics Recent Development
Table 150. Gilead Sciences Company Details
Table 151. Gilead Sciences Business Overview
Table 152. Gilead Sciences Product
Table 153. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 154. Gilead Sciences Recent Development
Table 155. Intercept Pharmaceuticals Company Details
Table 156. Intercept Pharmaceuticals Business Overview
Table 157. Intercept Pharmaceuticals Product
Table 158. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 159. Intercept Pharmaceuticals Recent Development
Table 160. Shire Plc Company Details
Table 161. Shire Plc Business Overview
Table 162. Shire Plc Product
Table 163. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 164. Shire Plc Recent Development
Table 165. NGM Biopharmaceuticals Company Details
Table 166. NGM Biopharmaceuticals Business Overview
Table 167. NGM Biopharmaceuticals Product
Table 168. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 169. NGM Biopharmaceuticals Recent Development
Table 170. Conatus Pharmaceuticals Company Details
Table 171. Conatus Pharmaceuticals Business Overview
Table 172. Conatus Pharmaceuticals Product
Table 173. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 174. Conatus Pharmaceuticals Recent Development
Table 175. Durect Corporation Company Details
Table 176. Durect Corporation Business Overview
Table 177. Durect Corporation Product
Table 178. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 179. Durect Corporation Recent Development
Table 180. Sirnaomics Company Details
Table 181. Sirnaomics Business Overview
Table 182. Sirnaomics Product
Table 183. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 184. Sirnaomics Recent Development
Table 185. Shenzhen HighTide Biopharmaceuticals Company Details
Table 186. Shenzhen HighTide Biopharmaceuticals Business Overview
Table 187. Shenzhen HighTide Biopharmaceuticals Product
Table 188. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2015-2020) (Million US$)
Table 189. Shenzhen HighTide Biopharmaceuticals Recent Development
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2020 VS 2026
Figure 2. Liver Transplantation Operation Features
Figure 3. UDCA Drugs Features
Figure 4. PSC Drugs Features
Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 10. Global Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2019
Figure 15. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2019
Figure 17. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 26. Glenmark Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 28. Impax Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 30. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 32. Teva Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 34. Dr. Falk Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 36. Daewoong Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 38. Epic Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 40. Mitsubishi Tanabe Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 42. Lannett Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 44. Bruschettini Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 46. Shanghai Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 48. Grindeks Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 50. Acorda Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 52. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 54. Intercept Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 56. Shire Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 58. NGM Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 60. Conatus Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 62. Durect Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2015-2020)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed